Boehringer buys cancer immunotherapy developer

Sep 13, 2018

Boehringer Ingelheim announced that it has acquired all shares of Austrian-based ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies.

The deal gives Boehringer full control over a preclinical viral-based cancer immunotherapy (VSV-GP) the companies have been co-developing for two years. The two companies are working to develop a next generation oncolytic viral therapy platform. VSV-GP, the lead investigational candidate leveraging the platform, has shown promising results in pre-clinical models, especially in combination with key immune modulatory principles Boehringer Ingelheim is developing.

The transaction (with a total value of $245M) follows a collaboration and option agreement signed between ViraTherapeutics and Boehringer Ingelheim in August 2016.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments